Natco Pharma gains 11% on semaglutide injection approval
Natco Pharma's stock shot up 11% after getting the green light to make and sell a generic version of semaglutide—a big-name diabetes injection—in India.
The company plans to launch it in March 2026, and investors clearly loved the news.
What is semaglutide and why is it important?
Semaglutide is a go-to treatment for adults with tough-to-manage type 2 diabetes. It helps the body release more insulin when needed and keeps blood sugar in check.
Natco received CDSCO approval to manufacture and market a generic semaglutide injection and plans to launch it in March 2026.
US exclusivity for Natco
Even with some recent regulatory bumps, Natco holds exclusive rights to key versions of Ozempic and Wegovy (both based on semaglutide) in the US—meaning no rivals for at least 30 months.
The company holds First-To-File exclusivity for the affected strengths.